HLA-DQ2 and HLA-DQ8 explained: the allele names on a celiac gene report
Short answer
Celiac disease almost always occurs in people who carry one of two groups of gene variants, DQ2 and DQ81. Coeliac UK reports that 99.6% of patients carry DQ2.5, DQ8 or DQ2.22, yet the NIDDK says about 30 percent of people have DQ2 or DQ8 and only about 3 percent of them develop celiac disease3. A positive result therefore does not confirm the diagnosis4.
Part of Celiac genetics and family risk, 15 guides

Key points
- DQ2.5 is the type most tied to celiac disease: Coeliac UK lists DQ2.5 as highest risk, DQ8 as moderate and DQ2.2 as low, but not no, risk5.
- A report that says only “DQ2” is ambiguous, because two different molecules have been called DQ2: DQ2.5 and DQ2.26, 7.
- In one US study of 10,191 people at risk, 28.28% of those with two copies of DQ2.5, or DQ2.2 plus DQ2.5, were positive for anti-endomysial antibodies, against 9.09% of those with one copy8, 9.
- Carrying DQ2 or DQ8 is common: the NIDDK puts it at about 30 percent of people3, and Coeliac UK at up to 40% of the general population10.
- Coeliac UK calls patients who carry none of DQ2.5, DQ8 or DQ2.2 “very rare”42, and ESPGHAN says earlier reports of up to 5% DQ2/DQ8-negative patients had several causes, one being the testing method11.
What the names on the report mean
HLA is a gene system on the short arm of chromosome 6, where Coeliac UK says the so-called disease association genes, or permissibility genes, are situated12. A review from a Sardinian research group says the HLA genes involved in celiac disease are located at HLA-DQA1 and HLA-DQB113. Each codes for one chain of a two-chain protein: the review describes DQA1 05:01 and DQB1 02:01, the two alleles most often linked to celiac disease, as encoding the alpha and beta chains of the protein called DQ214, which is DQ2.5 in the finer naming15.
The report then names the finished protein. The table shows which alleles stand behind each name, with what the sources say about its link to celiac disease.
| Name on the report | Alleles that encode it | What the sources say about celiac risk |
|---|---|---|
| DQ2.5 | DQA1 05:01 with DQB1 02:0115 | Highest risk of the three types, per Coeliac UK5. The Sardinian review calls it the type most permissive for celiac disease16. |
| DQ2.2 | DQA1 02:01 with DQB1 02:0215 | Low risk, but not no risk, per Coeliac UK5. The review says its alpha chain makes it less suited than DQ2.5 to present gluten-derived peptides to T cells17. |
| DQ8 | DQA1 03:01 with DQB1 03:0218 | Moderate risk, per Coeliac UK5. The review says DQ8 without DQ2.5 confers a low risk19 and DQ8 together with DQ2.5 a high risk20. |
| DQ7.3 or DQ9 | DQA1 03 with DQB1 03:01 (DQ7.3), or with DQB1 03:03 (DQ9)21 | Not DQ8: the review says only DQ8 is permissive for celiac disease21. |
Two cautions when matching a report to this table. First, “DQ2” alone does not say which molecule: the DQ2.2 molecule “has been named” DQ2 as well, although its alpha chain is different6, and the two differ in how they relate to celiac disease7. Second, allele numbers are written at different levels of detail. A 2009 US study wrote DQ2.2 as DQA1 0201-DQB1 028; the 2025 review writes DQA1 02:01 and DQB1 02:0215. Coeliac UK says of UK laboratories that the format of the reporting is not standardised22.
How often each type appears in people with celiac disease
The figures depend on who was studied and how they were typed, so the table keeps each one next to its source instead of merging them.
| Source and group | DQ2 or DQ2.5 | DQ8 | Other, or neither |
|---|---|---|---|
| Coeliac UK: patients, adults and children | Not given separately | Not given separately | 99.6% carry DQ2.5, DQ8 or DQ2.22 |
| Review from a Sardinian group (2025) | Approximately 90%-95% positive for alleles that encode DQ2, more specifically DQ2.5 in cis or trans23 | About 5%-7%18 | The remaining 3%-5%: DQ2.2, or very rarely half heterodimers such as DQ2.3 or DQ7.524 |
| World Gastroenterology Organisation guideline (2016): patients of northern European descent | Approximately 95%25 | The rest25 | Not given |
| 437 Italian children with celiac disease (2009) | 91% carried DQ2 and/or DQ8, reported together26 | Counted with DQ226 | 6% had only the beta2 chain, 2% were alpha5 positive, and four children were negative for DQ2, DQ8, beta2 and alpha526 |
The rows come from different groups, methods and years and are not meant to be added together. “Cis” and “trans” in the review’s wording describe where the alleles sit: cis means alleles at different loci on the same chromosome, trans means they sit on opposite chromosomes27.
How the combinations compare in one US study
A 2009 US study typed the DNA of 10,191 people who were at risk for celiac disease and counted who tested positive for anti-endomysial antibodies (EMA), the marker the authors used to identify celiac disease28. The people were selected for being at risk, so the rates below are not rates for people in general.
| Genotype group | Share of the 10,191 samples | EMA-positive within the group |
|---|---|---|
| Two copies of DQ2.5, or DQ2.2 with DQ2.5 | 5.38%8 | 28.28% (95% CI 24.55-32.26)8 |
| DQ2.5 heterozygous | Not in the abstract | 9.09% (95% CI 7.82-10.51)9 |
| DQ8 homozygous | Not in the abstract | 8.42% (95% CI 3.71-15.92)29 |
| DQ8 heterozygous | Not in the abstract | 2.11% (95% CI 1.43-3.00)29 |
| DQ2.2 with DQ8, or DQ2.5 with DQ8 | 5.08%30 | 11.78% (95% CI 9.13-14.87)30 |
| Neither DQ2 nor DQ8 | 42.03%, 4283 samples31 | 0.16% (95% CI 0.07-0.34)31 |
“Homozygous” means the same allele on both chromosomes and “heterozygous” means different alleles, in the wording of the 2025 review’s glossary27.
One copy or two copies of DQ2.5
In the US study, the group with two copies of DQ2.5 (or DQ2.2 plus DQ2.5) had a higher EMA-positive rate than the group with one copy: 28.28% against 9.09%8, 9. The authors wrote that the data suggest a quantitative relationship between the type and proportion of DQ heterodimers and the risk of celiac disease32.
A laboratory study from 2003 found a matching pattern: cells with two copies of DQ2 presented gluten to T cells better than cells with one DQ2 copy and a non-DQ2 allele33. The same group reported that DQ2.5 presents a large repertoire of gluten peptides, whereas DQ2.2 can present only a subset34, and said the findings explain the strongly increased risk for people homozygous for DQ2.5 and for DQ2.2/2.5 heterozygous people35.
That is why DQ2.2 reads differently depending on what sits beside it. The 2025 review lists DQ2.5/DQ2.2, DQ2.5/DQ2.5 and DQ2.5/DQ8 among the high-risk genotypes36. It explains that DQ2.2 can behave as a donor of beta chains for building the DQ2.5 protein37, and that when DQ2.2 combines with DQA1 05:05 and DQB1 03:01 to form the DQ2.5 protein in trans, it confers a similar risk to DQ2.5 formed in cis38.
How common DQ2 and DQ8 are in people without celiac disease
Both types are common. The NIDDK says about 30 percent of people have DQ2 or DQ8, and only about 3 percent of people with DQ2 or DQ8 develop celiac disease3. Coeliac UK says the DQ2 and DQ8 haplotypes are found in up to 40% of the general population10, and the World Gastroenterology Organisation guideline gives 30–35% for the general population, against approximately 70% of first-degree relatives39.
Coeliac UK reasons that, with celiac disease estimated at 1% in the UK, “there must be other factors” that work with these haplotypes10.
What the DQ protein does with gluten
A 2015 review by du Pré and Sollid says CD4+ T cells that recognize gluten peptides bound to predisposing HLA-DQ molecules play a key role in celiac disease. These T cells recognize deamidated gluten peptides better, and the enzyme transglutaminase 2 (TG2) does the deamidating40.
A 2017 review by Sollid puts it as certain HLA-DQ allotypes predisposing to the disease by presenting these modified gluten peptides to CD4+ T cells41.
Celiac disease without DQ2 or DQ8
Coeliac UK calls patients who carry none of DQ2.5, DQ8 or DQ2.2 “very rare”42. The sources give these figures and explanations:
- An Australasian group of 356 people with celiac disease: 99.6% were DQ2/DQ8-positive, as ESPGHAN’s 2020 guideline reports11.
- ESPGHAN says the higher percentage of DQ2/DQ8-negative patients (up to 5%) in earlier publications had several causes, one being the HLA testing method11. SNP-based tests recognize the common variants (DQ2.5, DQ8, DQ2.2, DQ7.5), while in-depth allele typing is needed to identify rare ones, so the accuracy of excluding celiac disease depends on the method used43. Other causes it lists are a more heterogeneous group of patients with compatible symptoms and, in some cases, false-positive histopathology44.
- In the US study, 0.16% of the 4283 samples with neither DQ2 nor DQ8 were EMA-positive31.
- Among 437 Italian children with celiac disease, four were negative for DQ2, DQ8, beta2 and alpha526.
- The 2025 Sardinian review says a multicenter European study detected patients with genotypes other than DQ2 and DQ8 in 2% of cases45. Its own series had 10 such patients, all diagnosed in the late 1980s before the tTG blood tests were available, and the authors could not re-verify those diagnoses46.
These figures come from different groups, methods and decades, so they are not one estimate.
What a positive or negative result does and does not show
The sources treat a negative result as more informative than a positive one. ESPGHAN’s guideline says that if a patient tests negative for DQ2 and DQ8 the risk of celiac disease is very low, while a positive result does not confirm the diagnosis4. The 2023 American College of Gastroenterology guideline says HLA testing may be helpful in selected situations47, and that if it is negative, celiac disease is ruled out48. Coeliac UK says a positive result does not diagnose celiac disease and, in its example of a patient with suspected celiac disease who tests positive, is not very helpful, because so many of the general population are DQ positive49. A 2025 review adds that the test has value only when negative50.
ESPGHAN also says HLA typing is not required in patients with positive TGA-IgA who qualify for diagnosis with biopsies, or who have high serum TGA-IgA (10 times the upper limit of normal or more) and positive EMA-IgA4.
The World Gastroenterology Organisation guideline says research suggests HLA haplotypes alone confer approximately 35–40% of the genetic risk51.
This guide explains terms. What a particular result means for a particular person is a question for that person’s clinician.
Questions people ask
Do DQ2 and DQ8 cause celiac disease on their own?
No. The NIDDK says research suggests celiac disease only occurs in people who have certain genes and eat food that contains gluten52, and not everyone with DQ2 or DQ8 who eats gluten develops it53.
Does a report without DQ2 or DQ8 mean celiac disease is impossible?
The sources word it differently. The NIDDK says people without these gene variants are very unlikely to develop celiac disease1; ESPGHAN says the risk is very low4; the 2023 American College of Gastroenterology guideline says that if HLA testing is negative, celiac disease is ruled out48. Coeliac UK says patients with none of DQ2.5, DQ8 or DQ2.2 are very rare and that being negative, though “never a guarantee”, would be very reassuring42.
What do homozygous, heterozygous, cis and trans mean on a report?
The 2025 review’s glossary defines homozygous as the same allele sequence at the same locus on both chromosomes, heterozygous as different sequences, cis as alleles at different loci on the same chromosome, and trans as alleles at different loci on opposite chromosomes27.
More in Celiac genetics and family risk
A positive celiac gene test in your child: what it means and what happens nextWhat a positive HLA (DQ2 or DQ8) result in a child means, why sources say gluten stays in the diet until testing, and what clinicians check next.
Celiac genetic testing: what HLA-DQ2 and DQ8 results can and cannot tell youWhat HLA-DQ2 and DQ8 typing checks for, how NIDDK, ACG, ESPGHAN and WGO read a negative or positive result, and where the guidelines place the test.
Gone gluten-free without testing: what an HLA gene test can settleWhat an HLA-DQ2/DQ8 gene test can and cannot settle if you stopped gluten before celiac testing, and what sources say a gluten challenge involves.
Carrying a celiac gene: how often it leads to celiac disease and what changes the oddsHow often people with the celiac gene variants develop celiac disease, how a relative with it changes the odds, and what is proven or only suspected.
Is celiac disease hereditary? What runs in families and what does notWhat NIDDK and pooled studies report on inherited risk for celiac disease: the DQ2 and DQ8 genes, twin data, and how rates differ among relatives.
23andMe versus a clinical HLA test for celiac disease: what each reads and what a negative meansWhich gene variants the FDA-authorized 23andMe celiac report and clinical HLA typing read, and how labs and charities describe a negative or positive.
Related guides
Sources
- [1, 3, 52, 53] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Celiac Disease: Symptoms & Causes, checked Nov 17, 2026.
- [2, 5, 10, 12, 22, 42, 49] Coeliac UK, Genetics and coeliac disease testing (for healthcare professionals), checked Nov 17, 2026.
- [4, 11, 43, 44] ESPGHAN (Journal of Pediatric Gastroenterology and Nutrition), European Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020, checked Nov 17, 2026.
- [6, 13, 14, 15, 16, 17, 18, 19, 20, 21, 23, 24, 27, 36, 37, 38, 45, 46, 50] World Journal of Gastroenterology, Clinical settings in which human leukocyte antigen typing is still useful in the diagnosis of celiac disease (2025), checked Nov 17, 2026.
Read on 2026-11-17: Table 1, “Genetic terminology used in the present manuscript”, defines homozygous as the presence of alleles with the same nucleotide sequence at the same locus on homologous chromosomes, heterozygous as the presence of alleles with different nucleotide sequences at the same locus, cis as alleles at different loci located on the same chromosome, and trans as alleles at different loci located on opposite chromosomes.
- [7, 33, 34, 35] Proceedings of the National Academy of Sciences, The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses (2003), checked Nov 17, 2026.
- [8, 9, 28, 29, 30, 31, 32] Clinical Gastroenterology and Hepatology, Stratifying risk for celiac disease in a large at-risk United States population by using HLA alleles (2009), checked Nov 17, 2026.
- [25, 39, 51] World Gastroenterology Organisation, Global Guidelines: Celiac disease (2016), checked Nov 17, 2026.
- [26] Human Immunology, HLA-DQ and risk gradient for celiac disease (2009), checked Nov 17, 2026.
- [40] Best Practice & Research Clinical Gastroenterology, T-cell and B-cell immunity in celiac disease (2015), checked Nov 17, 2026.
- [41] Immunogenetics, The roles of MHC class II genes and post-translational modification in celiac disease (2017), checked Nov 17, 2026.
- [47, 48] American College of Gastroenterology (American Journal of Gastroenterology), ACG Guidelines Update: Diagnosis and Management of Celiac Disease (2023), checked Nov 17, 2026.
